

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/049636 A1

(51) International Patent Classification:

C07C 55/08 (2006.01) C07C 215/34 (2006.01)
A61P 37/08 (2006.01)

(21) International Application Number:

PCT/US2024/044275

(22) International Filing Date:

28 August 2024 (28.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/535,184 29 August 2023 (29.08.2023) US
63/573,095 02 April 2024 (02.04.2024) US

(71) Applicant: **BIOTHEA PHARMA, INC.** [US/US]; 2 Avery Street, Suite 21E, Boston, Massachusetts 02111 (US).

(72) Inventors: **SOMMADOSSI, Jean-Pierre**; 2 Avery Street, Suite 21E, Boston, Massachusetts 02110 (US). **MOUSSA, Adel**; 9 Chandler Road, Burlington, Massachusetts 01803 (US).

(74) Agent: **POSTAL, Brett A.** et al.; Rothwell, Figg, Ernst & Manbeck, P.C., 901 New York Ave., NW, Suite 900 East, Washington, District of Columbia 20001 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: POLYMORPHIC FORMS OF EPINEPHRINE MALONATE




FIG. 7

(57) Abstract: Polymorphic forms of crystalline epinephrine malonate salt, including Form A, Form B, and Form C of crystalline epinephrine malonate salt. Also described are pharmaceutical compositions comprising one or more the polymorphic forms and methods for treating a patient comprising administering a pharmaceutical composition of one of the polymorphic forms of crystalline epinephrine malonate.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*